Genestack

Genestack

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.5M

Overview

Genestack is a private, revenue-generating bioinformatics platform company addressing the critical data integration challenges in life science R&D. Its primary offering, the Open Data Manager (ODM), creates a centralized, FAIR-compliant data catalog that enables AI-driven research by harmonizing diverse data types like genomics, proteomics, and radiomics. The company serves a blue-chip client base including top-10 biopharma firms like AstraZeneca, leading agriscience companies like Bayer and Bejo, and prestigious academic institutions like the Wellcome Sanger Institute. Founded by a former EBI group leader and established as a joint venture with software tool giant JetBrains, Genestack is positioned as a key enabler for accelerating drug discovery, precision medicine, and agricultural innovation.

BioinformaticsData Management

Technology Platform

Open Data Manager (ODM): A FAIR-compliant, AI-ready data catalog and harmonization platform for multi-omics, imaging, and other biological data. It features AI-powered curation, integrative search, and API-driven integration without requiring data migration.

Funding History

2
Total raised:$7.5M
Series A$6M
Seed$1.5M

Opportunities

The massive growth of multi-omics and imaging data, coupled with the industry-wide shift to AI-driven R&D, creates a urgent need for FAIR data management platforms.
Expansion into new verticals like diagnostics, CROs, and broader healthcare, as well as geographic growth, present significant scalable opportunities.

Risk Factors

Faces intense competition from large informatics vendors and cloud hyperscalers.
Long enterprise sales cycles and customer concentration risk.
Must continuously innovate to keep pace with rapidly evolving AI/ML technologies and data types while ensuring robust data security and compliance.

Competitive Landscape

Genestack competes in a crowded market with established bioinformatics platforms (e.g., DNAnexus, Partek), cloud-native solutions from AWS/Google/Microsoft, and a fragmented landscape of open-source tools. Its differentiation lies in its specific focus on FAIR data harmonization for AI, a 'no migration' architecture, and strong validation from top-tier life science enterprises.